Page last updated: 2024-10-20

pyrazinamide and AIDS Seroconversion

pyrazinamide has been researched along with AIDS Seroconversion in 17 studies

pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.

Research Excerpts

ExcerptRelevanceReference
" Peak drug exposure to isoniazid was lower in patients with diarrhea."3.69Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. ( Cameron, DW; Gallicano, K; Garber, G; Oliveras, L; Rachlis, A; Sahai, J; Seguin, I; Swick, L; Tailor, S; Walker, S, 1997)
" We investigated the incidence of adverse events and cure rates according to HIV status for patients receiving standard TB therapy in the trial."2.90Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status. ( Crook, AM; Dawson, R; Diacon, AH; Gillespie, SH; McHugh, TD; Mendel, CM; Meredith, SK; Mohapi, L; Murphy, ME; Nunn, AJ; Phillips, PPJ; Singh, KP; Spigelman, M; Tweed, CD, 2019)
"Optimum treatment of tuberculosis in persons with human immunodeficiency virus (HIV) infection is still being defined."2.38Failure of therapy for tuberculosis in human immunodeficiency virus infection. ( Nolan, CM, 1992)
"Major adverse reactions to antituberculosis drugs can cause significant morbidity, and compromise treatment regimens for tuberculosis (TB)."1.32Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. ( Menzies, D; Parisien, I; Pelletier, M; Rocher, I; Valiquette, C; Yee, D, 2003)
"Ethambutol was recovered from human urine quantitatively and stable for a period of at least one week in urine stored at -20 degrees C."1.32Standardization of the method for estimation of ethambutol in pharmaceutical preparations and biological fluid. ( Bhagavathy, S; Gayathri, TN; Gurumurthy, P; Venkatesan, P, 2004)

Research

Studies (17)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's8 (47.06)18.2507
2000's3 (17.65)29.6817
2010's5 (29.41)24.3611
2020's1 (5.88)2.80

Authors

AuthorsStudies
Tweed, CD1
Crook, AM2
Dawson, R1
Diacon, AH1
McHugh, TD3
Mendel, CM2
Meredith, SK2
Mohapi, L1
Murphy, ME1
Nunn, AJ3
Phillips, PPJ1
Singh, KP1
Spigelman, M1
Gillespie, SH3
Peetluk, LS1
Rebeiro, PF1
Cordeiro-Santos, M1
Kritski, A1
Andrade, BB1
Durovni, B1
Calvacante, S1
Arriaga, MB1
Turner, MM1
Figueiredo, MC1
Rolla, VC1
Sterling, TR1
Murray, SR1
Pappas, F1
Phillips, PP2
Jindani, A1
Harrison, TS1
Churchyard, GJ1
Charalambous, S1
Hatherill, M1
Geldenhuys, H1
McIlleron, HM1
Zvada, SP1
Mungofa, S1
Shah, NA1
Zizhou, S1
Magweta, L1
Shepherd, J1
Nyirenda, S1
van Dijk, JH1
Clouting, HE1
Coleman, D1
Bateson, AL1
Butcher, PD1
Mitchison, DA2
Khajotia, R1
Manthari, K1
Tripathy, S1
Anand, A1
Inamdar, V1
Manoj, MM1
Khillare, KM1
Datye, AS1
Iyer, R1
Kanoj, DM1
Thakar, M1
Kale, V1
Pereira, M1
Risbud, AR1
Chakaya, JM1
Kibuga, D1
Ng'ang'a, L1
Githui, WA1
Mansoer, JR1
Gakiria, G1
Kwamanga, D1
Maende, J1
Yee, D1
Valiquette, C1
Pelletier, M1
Parisien, I1
Rocher, I1
Menzies, D1
Gurumurthy, P1
Gayathri, TN1
Bhagavathy, S1
Venkatesan, P1
Kennedy, N1
Fox, R1
Kisyombe, GM1
Saruni, AO1
Uiso, LO1
Ramsay, AR1
Ngowi, FI1
Delaney, V1
Sumrani, N1
Hong, JH1
Sommer, B1
Kassim, S1
Sassan-Morokro, M1
Ackah, A1
Abouya, LY1
Digbeu, H1
Yesso, G1
Coulibaly, IM1
Coulibaly, D1
Whitaker, PJ1
Doorly, R1
Sahai, J1
Gallicano, K1
Swick, L1
Tailor, S1
Garber, G1
Seguin, I1
Oliveras, L1
Walker, S1
Rachlis, A1
Cameron, DW1
Nolan, CM1

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomised Placebo - Controlled Double Blind Trial Comparing 1) a Two Month Intensive Phase of Ethambutol, Moxifloxacin, Rifampicin, Pyrazinamide Versus the Standard Regimen (Ethambutol, Isoniazid, Rifampicin, Pyrazinamide) and 2) a Treatment Shortening[NCT00864383]Phase 31,931 participants (Actual)Interventional2008-01-31Completed
Using Biomarkers to Predict TB Treatment Duration[NCT02821832]Phase 2946 participants (Actual)Interventional2017-06-21Active, not recruiting
A Prospective, Randomized Controlled Study for the Efficacy and Safety of the Substitution of Pyrazinamide and Ethambutol With Moxifloxacin During the Intensive Phase of Treatment of Pulmonary Tuberculosis[NCT04187469]286 participants (Anticipated)Interventional2020-03-01Not yet recruiting
Randomized Clinical Trial to Assess the Efficacy of Short Course Intermittent Regimens for the Treatment of HIV-Associated Tuberculosis[NCT00376012]Phase 3300 participants (Actual)Interventional2001-02-28Active, not recruiting
TB Treatment Support Tools: Refinement and Evaluation of an Interactive Mobile App and Direct Adherence Monitoring on TB Treatment Outcomes[NCT04221789]555 participants (Actual)Interventional2020-11-17Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Combined Failure of Bacteriological Cure and Relapse as Defined by Culture Using Liquid Media (Mycobacteria Growth Indicator Tube-MGIT).

The secondary analysis of efficacy outcome was the proportion of patients who had bacteriologically or clinically defined failure or relapse within 18 months after randomization (a composite unfavorable outcome) based on MGIT. Culture-negative status was defined as two negative-culture results at different visits without an intervening positive result. The date of culture-negative status was defined as the date of the first negative-culture result. This status continued until there were two positive cultures, without an intervening negative culture, or until there was a single positive culture that was not followed by two negative cultures. Relapse strains were those shown to be identical on 24-locus Mycobacterial interspersed repetitive units (MIRU) analysis. (NCT00864383)
Timeframe: 18 months (within one year of completion of therapy)

Interventionparticipants with failure or relapse (Number)
Regimen 1 - 2EHRZ/4HR (Control Regimen)65
Regimen 2 - 2MHRZ/2MHR98
Regimen 3 - 2EMRZ/2MR131

Combined Failure of Bacteriological Cure and Relapse Within One Year of Completion of Therapy as Defined by Culture Using Solid Media (Lowenstein-Jensen - LJ).

The primary efficacy outcome was the proportion of patients who had bacteriologically or clinically defined failure or relapse within 18 months after randomization (a composite unfavorable outcome). Culture-negative status was defined as two negative-culture results at different visits without an intervening positive result. The date of culture-negative status was defined as the date of the first negative-culture result. This status continued until there were two positive cultures, without an intervening negative culture, or until there was a single positive culture that was not followed by two negative cultures. Relapse strains were those shown to be identical on 24-locus Mycobacterial interspersed repetitive units (MIRU) analysis. For the final 18 month study visit when both L-J samples were contaminated or missing, if the subject could not be brought back, liquid medium culture results were used in place of solid medium culture results. (NCT00864383)
Timeframe: 18 months (within one year of completion of therapy)

Interventionparticipants with failure or relapse (Number)
Regimen 1 - 2EHRZ/4HR (Control Regimen)43
Regimen 2 - 2MHRZ/2MHR78
Regimen 3 - 2EMRZ/2MR105

Number of Patients Who Are Culture Negative (Liquid MGIT Culture)

Number of patients who are TB MGIT culture negative at 8 weeks. (NCT00864383)
Timeframe: 8 weeks

Interventionparticipants who are culture negative (Number)
Regimen 1 - 2EHRZ/4HR (Control Regimen)235
Regimen 2 - 2MHRZ/2MHR274
Regimen 3 - 2EMRZ/2MR260

Number of Patients Who Are Culture Negative (Solid LJ Culture)

Number of patients who are TB LJ culture negative at 8 weeks. (NCT00864383)
Timeframe: 8 weeks

Interventionparticipants who are culture negative (Number)
Regimen 1 - 2EHRZ/4HR (Control Regimen)352
Regimen 2 - 2MHRZ/2MHR394
Regimen 3 - 2EMRZ/2MR401

Number of Patients With Grade 3 or 4 Adverse Events (Using a Modified Division of Acquired Immunodeficiency Syndrome National Institute of Allergy and Infectious Diseases [DAIDS] Scale of Adverse Event Reporting)

The number of participants includes all patients who had at least one grade 3 or 4 adverse event. (NCT00864383)
Timeframe: 18 months (within one year of completion of therapy)

Interventionparticipants with Grade 3 or 4 AEs (Number)
Regimen 1 - 2EHRZ/4HR (Control Regimen)123
Regimen 2 - 2MHRZ/2MHR127
Regimen 3 - 2EMRZ/2MR111

Sensitivity Analyses Assuming All Losses to Follow-up and Non-tuberculous Deaths Have a Favourable Outcome Using Solid (L-J) Media.

"Sensitivity Analysis of Primary Efficacy Results of All Randomized Subjects Imputing Favorable for Missing Outcomes. Analysis is the number of subjects with an unfavorable outcome. Favorable outcome is defined as the number of subjects with a negative TB culture status at 18 months (at or after 72 weeks), who had not already been classified as having an unfavorable outcome, and whose last positive TB culture result (isolated positive culture) was followed by at least two negative culture results." (NCT00864383)
Timeframe: 18 months

Interventionparticipants with unfavorable outcome (Number)
Regimen 1 - 2EHRZ/4HR (Control Regimen)87
Regimen 2 - 2MHRZ/2MHR132
Regimen 3 - 2EMRZ/2MR132

Sensitivity Analysis Assuming All Losses to Follow-up and Non-tuberculous Deaths Have an Unfavorable Outcome Using Solid (L-J) Media.

"Sensitivity Analysis of Primary Efficacy Results of All Randomized Subjects Imputing Unfavorable for Missing Outcomes. Analysis is the number of subjects with an unfavorable outcome. Favorable outcome is defined as the number of subjects with a negative TB culture status at 18 months (at or after 72 weeks), who had not already been classified as having an unfavorable outcome, and whose last positive TB culture result (isolated positive culture) was followed by at least two negative culture results." (NCT00864383)
Timeframe: 18 months

Interventionparticipants with unfavorable outcome (Number)
Regimen 1 - 2EHRZ/4HR (Control Regimen)172
Regimen 2 - 2MHRZ/2MHR219
Regimen 3 - 2EMRZ/2MR217

Time to First Culture Negative Sputum Sample (LJ Solid Media)

Culture negative for TB using LJ cultures. (NCT00864383)
Timeframe: 18 months

InterventionTime to culture negative status / weeks (Median)
Regimen 1 - 2EHRZ/4HR (Control Regimen)6.0
Regimen 2 - 2MHRZ/2MHR6.0
Regimen 3 - 2EMRZ/2MR6.0

Time to First Culture Negative Sputum Sample (MGIT Liquid Media)

(NCT00864383)
Timeframe: 18 months

InterventionTime to culture negative status / weeks (Median)
Regimen 1 - 2EHRZ/4HR (Control Regimen)11.9
Regimen 2 - 2MHRZ/2MHR8.0
Regimen 3 - 2EMRZ/2MR8.0

Comparison of the Rate of Treatment Success at 18 Months (After Treatment Initiation) Between Arms B and C

Estimation of the lower bound of a one-sided 95% confidence interval of the difference in success rates between arms B and C. If the lower bound is greater than -7%, this will be evidence that the treatment-shortening arm is not inferior to the standard duration arm. (NCT02821832)
Timeframe: 18 months

,,
InterventionParticipants (Count of Participants)
CuredConfirmed relapsesLate withdrawal, lost to follow-upProbable relapsesTreatment Failure
Arm A21751311
Arm B1211910
Arm C1179634

Reviews

1 review available for pyrazinamide and AIDS Seroconversion

ArticleYear
Failure of therapy for tuberculosis in human immunodeficiency virus infection.
    The American journal of the medical sciences, 1992, Volume: 304, Issue:3

    Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Drug Therapy, Combi

1992

Trials

5 trials available for pyrazinamide and AIDS Seroconversion

ArticleYear
Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status.
    BMC pulmonary medicine, 2019, Aug-14, Volume: 19, Issue:1

    Topics: Adult; Antitubercular Agents; Ethambutol; Female; HIV Seropositivity; Humans; Incidence; Isoniazid;

2019
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi

2014
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi

2014
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi

2014
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi

2014
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi

2014
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi

2014
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi

2014
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi

2014
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi

2014
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adolescent; Adult; Antitubercular Agents; Coinfection; Drug Administration Schedule; Drug Therapy, C

2014
Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis.
    The American review of respiratory disease, 1993, Volume: 148, Issue:6 Pt 1

    Topics: Adult; Aged; Ciprofloxacin; Drug Therapy, Combination; Ethambutol; Female; HIV Seropositivity; HIV-1

1993
Two-year follow-up of persons with HIV-1- and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa.
    AIDS (London, England), 1995, Volume: 9, Issue:10

    Topics: Adolescent; Adult; Africa, Western; AIDS-Related Opportunistic Infections; Antibiotics, Antitubercul

1995

Other Studies

11 other studies available for pyrazinamide and AIDS Seroconversion

ArticleYear
Lack of Weight Gain During the First 2 Months of Treatment and Human Immunodeficiency Virus Independently Predict Unsuccessful Treatment Outcomes in Tuberculosis.
    The Journal of infectious diseases, 2020, 04-07, Volume: 221, Issue:9

    Topics: Adult; Antitubercular Agents; Brazil; Ethambutol; Female; HIV Seropositivity; Humans; Isoniazid; Mal

2020
An apparently healthy young man with a peculiar-looking chest radiograph.
    Canadian family physician Medecin de famille canadien, 2011, Volume: 57, Issue:3

    Topics: Adult; Antibiotics, Antitubercular; Drug Therapy, Combination; Ethambutol; Fever; HIV Seropositivity

2011
Clinical response of newly diagnosed HIV seropositive & seronegative pulmonary tuberculosis patients with the RNTCP Short Course regimen in Pune, India.
    The Indian journal of medical research, 2011, Volume: 133

    Topics: Adult; Antitubercular Agents; Communicable Disease Control; Directly Observed Therapy; Enzyme-Linked

2011
Tuberculosis re-treatment outcomes within the public service in Nairobi, Kenya.
    East African medical journal, 2002, Volume: 79, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; AIDS-Related Opportunistic Infections; Antitubercular Ag

2002
Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.
    American journal of respiratory and critical care medicine, 2003, Jun-01, Volume: 167, Issue:11

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antitubercular Agents; Chemical and Drug In

2003
Standardization of the method for estimation of ethambutol in pharmaceutical preparations and biological fluid.
    Indian journal of experimental biology, 2004, Volume: 42, Issue:1

    Topics: Antitubercular Agents; Chemistry, Clinical; Chromatography; Dose-Response Relationship, Drug; Ethamb

2004
Mycobacterial infections in renal allograft recipients.
    Transplantation proceedings, 1993, Volume: 25, Issue:3

    Topics: Drug Therapy, Combination; Ethambutol; HIV Seropositivity; Humans; Immunosuppressive Agents; Isoniaz

1993
Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection.
    Annals of internal medicine, 1997, Aug-15, Volume: 127, Issue:4

    Topics: Adult; Aged; Antitubercular Agents; Case-Control Studies; Diarrhea; Ethambutol; Female; HIV Infectio

1997
How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 1998, Volume: 2, Issue:1

    Topics: AIDS-Related Opportunistic Infections; Antibiotics, Antitubercular; Antitubercular Agents; Drug Admi

1998
Transmission of multidrug-resistant tuberculosis among immunocompromised persons in a correctional system--New York, 1991.
    MMWR. Morbidity and mortality weekly report, 1992, Jul-17, Volume: 41, Issue:28

    Topics: Antitubercular Agents; Drug Resistance, Microbial; Ethambutol; Ethionamide; HIV Seropositivity; Huma

1992
From the Centers for Disease Control. Transmission of multidrug-resistant tuberculosis among immunocompromised persons, correctional system--New York, 1991.
    JAMA, 1992, Aug-19, Volume: 268, Issue:7

    Topics: Antitubercular Agents; Drug Resistance, Microbial; Ethambutol; Ethionamide; HIV Seropositivity; Huma

1992